Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B

Cancer

Volumn 121, Issue 20, 2015, Pages 3631-3638

  Kim, W Ray ^a   Loomba, Rohit ^b   Berg, Thomas ^c   Aguilar Schall, Raul E ^d   Yee, Leland J ^d   Dinh, Phillip V ^d   Flaherty, John F ^d   Martins, Eduardo B ^d   Therneau, Terry M ^e   Jacobson, Ira ^f   Fung, Scott ^g   Gurel, Selim ^h   Buti, Maria ⁱ   Marcellin, Patrick ^j  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d GILEAD SCIENCES   (United States)

^e MAYO CLINIC   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h ULUDAG UNIVERSITY   (Turkey)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j BEAUJON HOSPITAL   (France)

more..

Author keywords

antiviral therapy; chronic hepatitis B; fumarate; hepatocellular carcinoma; REACH B; tenofovir disoproxil

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; TENOFOVIR;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHRONIC HEPATITIS B; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REGISTER; RISK ESTIMATION FOR HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B; STANDARDIZED INCIDENCE RATIO; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DRUG ADMINISTRATION; HEPATITIS B, CHRONIC; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK ASSESSMENT; TENOFOVIR;

EID: 84943531655     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29537     Document Type: Article

References (28)

1. World Health Organization. WHO Fact Sheet No. 204 on Hepatitis B. Updated July 2013. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ 2013. Accessed January 2014.
2. Lee WM,. Hepatitis B virus infection. N Engl J Med. 1997; 337: 1733-1745.
3. El-Serag HB,. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142: 1264-1273.e1.
4. Loomba R, Yang HI, Su J, et al., Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol. 2013; 177: 333-342.
5. Loomba R, Liu J, Yang HI, et al,; REVEAL-HBV Study Group. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013; 11: 1636-1645.e1-3.
6. Fattovich G, Stroffolini T, Zagni I, Donato F,. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127 (5 suppl 1): S35-S50.
7. Chen CJ, Yang HI, Su J, et al., Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295: 65-73.
8. McMahon BJ,. Natural history of chronic hepatitis B. Clin Liver Dis. 2010; 14: 381-396.
9. Wong VW, Chan SL, Mo F, et al., Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010; 28: 1660-1665.
10. Yang HI, Yuen MF, Chan HL, et al., Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011; 12: 568-574.
11. Yuen MF, Tanaka Y, Fong DY, et al., Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009; 50: 80-88.
12. Petersen J, Buti M,. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Rev Gastroenterol Hepatol. 2012; 6: 683-693; quiz 694.
13. Marcellin P, Gane E, Buti M, et al., Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013; 381: 468-475.
14. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A,. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010; 53: 348-356.
15. Marcellin P, Heathcote EJ, Buti M, et al., Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359: 2442-2455.
16. Heathcote EJ, Marcellin P, Buti M, et al., Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011; 140: 132-143.
17. Ulm K,. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol. 1990; 131: 373-375.
18. Atkinson EJ, Crowson CS, Pedersen RA, Therneau TM,. Poisson models for person-years and expected rates. Technical Report Series No. 81. Rochester, MN: Department of Health Science Research, Mayo Clinic; 2008: 1-43.
19. Arends P, Sonneveld M, Zoutendijk R, et al,; for the VIRGIL Surveillance Study Group. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians [published online ahead of print July 10, 2014 ]. Gut. doi: 10.1136/gutjnl-2014-307023.
20. Abu-Amara M, Cerecchi O, Mahli G, et al., The risk of hepatitis B-related hepatocellular carcinoma (HCC) is reduced with antiviral therapy: evidence from 3 HCC prediction models. London: European Association for the Study of the Liver; Poster #194. 2014.
21. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF,. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999; 29: 971-975.
22. Liaw YF, Sung JJ, Chow WC, et al., Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351: 1521-1531.
23. Gordon S, Lamerato L, Rupp L, et al,; CHeCS Investigators. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol. 2014; 12: 885-893.
24. Yin J, Li N, Han Y, et al., Effect of antiviral treatment with nucleotide/nucleoside analogs on post-operative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013; 31: 3647-3655.
25. Wong GL, Chan HL, Chan HY, et al., Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013; 144: 933-944.
26. Cho JY, Paik YH, Sohn W, et al., Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014; 63: 1943-1950.
27. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
28. Sherman M, Bruix J, Porayko M, Tran T,; AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases Recommendation. Hepatology. 2012; 56: 793-796.